In The News

The US Food and Drug Administration (FDA) has granted marketing approval for the BrainsWay deep transcranial magnetic stimulation (TMS) system to help adult smokers kick tobacco.

The FDA has cleared MagVenture TMS Therapy® for adjunct treatment of Obsessive-Compulsive Disorder (OCD) in adult patients*.

Dr. Colleen Hanlon discusses Transcranial Magnetic Stimulation and her most recent paper in Translational Psychiatry.

Approximately 50% to 60% of people with depression who have tried and failed to receive benefit from medications experience a clinically meaningful response with TMS.

People with other chronic medical conditions have a higher risk of depression. Seek help if this is you.

Almost a third of people diagnosed with clinical depression do not respond to medication or talk therapy.

“For some study participants, this was the first time in years that they experienced any relief in symptoms,”

FDA-Cleared, non-invasive, well-tolerated outpatient treatment clinically proven to improve the symptoms of Major Depression, even in treatment-resistant patients.

Major depressive disorder is a debilitating disease believed to affect more than 300 million people worldwide. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide (1, 2).

The Brain Stimulation Service Center (BSSC) is a core research facility in the Duke University School of Medicine that provides equipment and technical services to carry out noninvasive neuromodulatory research studies using Transcranial Magnetic Stimulat